Research Article
Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies
Table 1
Nominal doses and exposures from both the nonphospholipogenic compound (NP) and phospholipogenic compound (P) datasets. Averages and standard deviations (in parentheses) shown. Data from mid-doses are not shown. Average phospholipogenic plasma exposures were lower for all species across all doses than exposures from the negative dataset, but differences were not statistically significant.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||